Skip to content

Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor in Increasing Pregnancy Rate in ICSI

Intra Uterine Injection of Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor at Ovum Pick up Day Significantly Increase Implantation Rate and Pregnancy Rate in Intra Cytoplasmic Sperm Injection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04606082
Enrollment
200
Registered
2020-10-28
Start date
2020-10-30
Completion date
2021-01-10
Last updated
2020-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Disorders

Brief summary

Intrauterine Granulocyte colony stimulating factor (GCSF) was compared with intrauterine Human Chorionic Gonadotropin (HCG) in increasing clinical pregnancy rate as a primary outcome and ultrasound imaging of gestational sac as a secondary outcome.

Detailed description

Two hundred females with history of recurrent implantation failure and undergoing Intracytoplasmic Sprem injection (ICSI) were randomized into two groups; the first group (100 patients) received intrauterine Granulocyte colony stimulating factor (GCSF) and the second group (100) received intrauterine Human Chorionic Gonadotropin (HCG) at ovum pick up day. The clinical pregnancy rate was evaluated as a primary outcome after 14 days and ultrasound imaging of gestational sac was evaluated as a secondary outcome after 6 weeks.

Interventions

GCSF was intrauterine injected once at ovum pick up day

500 IU of HCG was injected intrauterine once at ovum pick up day

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Females suffering from recurrent implantation failure and undergoing ICSI

Exclusion criteria

* presence of comorbidity as diabetes, hypertension, heart diseases, or endocrine disorders

Design outcomes

Primary

MeasureTime frameDescription
clinical pregnancy rateafter 14 days from positive pregnancy testClinical pregnancy was evaluated by high HCG levels

Secondary

MeasureTime frameDescription
Gestational sac imaging6 weeks of pregnancyultrasound imaging of Gestational sac after 6 weeks of pregnancy

Contacts

Primary ContactElsayed Eldesouky
elsayedeldesouky@yahoo.com00201092934978

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026